Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma
Ets-1 proto-oncogene is a transcription factor involved in several cellular functions, including the activation of several proteases participating in tumor invasion and metastasis. The objective of this study was to analyze the possible correlation between Ets-1 mRNA expression and survival in advan...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2001-03, Vol.7 (3), p.551-557 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 557 |
|---|---|
| container_issue | 3 |
| container_start_page | 551 |
| container_title | Clinical cancer research |
| container_volume | 7 |
| creator | DAVIDSON, Ben REICH, Reuven GOLDBERG, Iris GOTLIEB, Walter H KOPOLOVIC, Juri BERNER, Aasmund BEN-BARUCH, Gilad BRYNE, Magne NESLAND, Jahn M |
| description | Ets-1 proto-oncogene is a transcription factor involved in several cellular functions, including the activation of several
proteases participating in tumor invasion and metastasis. The objective of this study was to analyze the possible correlation
between Ets-1 mRNA expression and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely
different disease outcome. Sections from 66 primary ovarian carcinomas and metastatic lesions from 41 patients diagnosed with
advanced-stage ovarian carcinoma (International Federation of Gynecologists and Obstetricians stages III and IV) were evaluated
for expression of Ets-1 using mRNA in situ hybridization. Patients were divided into long-term ( n = 17) and short-term ( n = 24) survivors. The mean values for disease-free survival and overall survival were 116 and 133 months for long-term survivors,
as compared to 3 and 21 months for short-term survivors, respectively. Expression of Ets-1 mRNA was detected in carcinoma
cells and stromal cells in 28 of 66 (42%) and 22 of 66 (33%) lesions, respectively. Ets-1 expression showed an association
with mRNA expression of vascular endothelial growth factor ( P = 0.001 for carcinoma cells; P = 0.004 for stromal cells), basic fibroblast growth factor ( P = 0.049 for carcinoma cells), and membrane type-1 matrix metalloproteinase ( P = 0.045), which were previously studied in this patient cohort. Ets-1 mRNA was detected more often in both carcinoma and
stromal cells in tumors of short-term survivors ( P = 0.038 for carcinoma cells). In univariate survival analysis for all cases, Ets-1 expression in both tumor ( P = 0.018) and stroma ( P = 0.026) correlated with poor survival. These findings were reproduced in an analysis of primary tumors alone ( P = 0.039 for tumor cells; P < 0.001 for stromal cells). Ets-1 mRNA expression in stromal cells retained its predictive power in a multivariate survival
analysis in which all molecules studied previously in this patient cohort were included ( P = 0.007). To our knowledge, this is the first evidence associating Ets-1 mRNA expression and poor survival in human epithelial
malignancy. Ets-1 is thus a novel prognostic marker in advanced-stage ovarian carcinoma. The association between Ets-1 mRNA
expression and the expression of membrane type-1 matrix metalloproteinase and angiogenic genes, first documented here in a
study of patient material, points to the central role of this transcription factor in tumor progres |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_77039138</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77039138</sourcerecordid><originalsourceid>FETCH-LOGICAL-h266t-bd4e6175efb9f099678445d0d7abaa0cd7993950e8d0ce2614854d91c6fbf6563</originalsourceid><addsrcrecordid>eNpN0FtLwzAUB_AiipvTryABwbdC0tyaxzGmDnYRb68hTdM12jYzWat-ewNO8ekcDj_O4fyPkjGilKc4Y_Q49pDnKSQ4GyVnIbxCiAiC5DQZIZQJnhE-Tl7m-5AisDIhmG5rPHhYT8H8c-fjwLoOLAJQYO0G04CV8m8RuArcO-fBY-8HO6gG2A5sBuWt6sBMeW0716rz5KRSTTAXhzpJnm_mT7O7dLm5Xcymy7TOGNunRUkMQ5yaqhAVFILxnBBawpKrQimoSy4EFhSavITaZAyRnJJSIM2qomKU4Uly_bN35917b8JetjZo0zSqM64PknOIBcJ5hJcH2BetKeXO21b5L_mbRARXB6CCVk3lVadt-HMCkyz_d6-22_rDeiN1dMbHuEz8vZZcYkkpwt-ZSXPE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77039138</pqid></control><display><type>article</type><title>Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>DAVIDSON, Ben ; REICH, Reuven ; GOLDBERG, Iris ; GOTLIEB, Walter H ; KOPOLOVIC, Juri ; BERNER, Aasmund ; BEN-BARUCH, Gilad ; BRYNE, Magne ; NESLAND, Jahn M</creator><creatorcontrib>DAVIDSON, Ben ; REICH, Reuven ; GOLDBERG, Iris ; GOTLIEB, Walter H ; KOPOLOVIC, Juri ; BERNER, Aasmund ; BEN-BARUCH, Gilad ; BRYNE, Magne ; NESLAND, Jahn M</creatorcontrib><description>Ets-1 proto-oncogene is a transcription factor involved in several cellular functions, including the activation of several
proteases participating in tumor invasion and metastasis. The objective of this study was to analyze the possible correlation
between Ets-1 mRNA expression and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely
different disease outcome. Sections from 66 primary ovarian carcinomas and metastatic lesions from 41 patients diagnosed with
advanced-stage ovarian carcinoma (International Federation of Gynecologists and Obstetricians stages III and IV) were evaluated
for expression of Ets-1 using mRNA in situ hybridization. Patients were divided into long-term ( n = 17) and short-term ( n = 24) survivors. The mean values for disease-free survival and overall survival were 116 and 133 months for long-term survivors,
as compared to 3 and 21 months for short-term survivors, respectively. Expression of Ets-1 mRNA was detected in carcinoma
cells and stromal cells in 28 of 66 (42%) and 22 of 66 (33%) lesions, respectively. Ets-1 expression showed an association
with mRNA expression of vascular endothelial growth factor ( P = 0.001 for carcinoma cells; P = 0.004 for stromal cells), basic fibroblast growth factor ( P = 0.049 for carcinoma cells), and membrane type-1 matrix metalloproteinase ( P = 0.045), which were previously studied in this patient cohort. Ets-1 mRNA was detected more often in both carcinoma and
stromal cells in tumors of short-term survivors ( P = 0.038 for carcinoma cells). In univariate survival analysis for all cases, Ets-1 expression in both tumor ( P = 0.018) and stroma ( P = 0.026) correlated with poor survival. These findings were reproduced in an analysis of primary tumors alone ( P = 0.039 for tumor cells; P < 0.001 for stromal cells). Ets-1 mRNA expression in stromal cells retained its predictive power in a multivariate survival
analysis in which all molecules studied previously in this patient cohort were included ( P = 0.007). To our knowledge, this is the first evidence associating Ets-1 mRNA expression and poor survival in human epithelial
malignancy. Ets-1 is thus a novel prognostic marker in advanced-stage ovarian carcinoma. The association between Ets-1 mRNA
expression and the expression of membrane type-1 matrix metalloproteinase and angiogenic genes, first documented here in a
study of patient material, points to the central role of this transcription factor in tumor progression in ovarian carcinoma.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 11297247</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Disease Progression ; Disease-Free Survival ; Endothelial Growth Factors - biosynthesis ; Female ; Female genital diseases ; Fibroblast Growth Factor 2 - biosynthesis ; Gynecology. Andrology. Obstetrics ; Humans ; In Situ Hybridization ; Lymphokines - biosynthesis ; Matrix Metalloproteinase 1 - biosynthesis ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Ovarian Neoplasms - metabolism ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; Prognosis ; Proto-Oncogene Protein c-ets-1 ; Proto-Oncogene Proteins - biosynthesis ; Proto-Oncogene Proteins c-ets ; RNA, Messenger - metabolism ; Time Factors ; Transcription Factors - biosynthesis ; Tumors ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors</subject><ispartof>Clinical cancer research, 2001-03, Vol.7 (3), p.551-557</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=934286$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11297247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DAVIDSON, Ben</creatorcontrib><creatorcontrib>REICH, Reuven</creatorcontrib><creatorcontrib>GOLDBERG, Iris</creatorcontrib><creatorcontrib>GOTLIEB, Walter H</creatorcontrib><creatorcontrib>KOPOLOVIC, Juri</creatorcontrib><creatorcontrib>BERNER, Aasmund</creatorcontrib><creatorcontrib>BEN-BARUCH, Gilad</creatorcontrib><creatorcontrib>BRYNE, Magne</creatorcontrib><creatorcontrib>NESLAND, Jahn M</creatorcontrib><title>Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Ets-1 proto-oncogene is a transcription factor involved in several cellular functions, including the activation of several
proteases participating in tumor invasion and metastasis. The objective of this study was to analyze the possible correlation
between Ets-1 mRNA expression and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely
different disease outcome. Sections from 66 primary ovarian carcinomas and metastatic lesions from 41 patients diagnosed with
advanced-stage ovarian carcinoma (International Federation of Gynecologists and Obstetricians stages III and IV) were evaluated
for expression of Ets-1 using mRNA in situ hybridization. Patients were divided into long-term ( n = 17) and short-term ( n = 24) survivors. The mean values for disease-free survival and overall survival were 116 and 133 months for long-term survivors,
as compared to 3 and 21 months for short-term survivors, respectively. Expression of Ets-1 mRNA was detected in carcinoma
cells and stromal cells in 28 of 66 (42%) and 22 of 66 (33%) lesions, respectively. Ets-1 expression showed an association
with mRNA expression of vascular endothelial growth factor ( P = 0.001 for carcinoma cells; P = 0.004 for stromal cells), basic fibroblast growth factor ( P = 0.049 for carcinoma cells), and membrane type-1 matrix metalloproteinase ( P = 0.045), which were previously studied in this patient cohort. Ets-1 mRNA was detected more often in both carcinoma and
stromal cells in tumors of short-term survivors ( P = 0.038 for carcinoma cells). In univariate survival analysis for all cases, Ets-1 expression in both tumor ( P = 0.018) and stroma ( P = 0.026) correlated with poor survival. These findings were reproduced in an analysis of primary tumors alone ( P = 0.039 for tumor cells; P < 0.001 for stromal cells). Ets-1 mRNA expression in stromal cells retained its predictive power in a multivariate survival
analysis in which all molecules studied previously in this patient cohort were included ( P = 0.007). To our knowledge, this is the first evidence associating Ets-1 mRNA expression and poor survival in human epithelial
malignancy. Ets-1 is thus a novel prognostic marker in advanced-stage ovarian carcinoma. The association between Ets-1 mRNA
expression and the expression of membrane type-1 matrix metalloproteinase and angiogenic genes, first documented here in a
study of patient material, points to the central role of this transcription factor in tumor progression in ovarian carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Endothelial Growth Factors - biosynthesis</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Fibroblast Growth Factor 2 - biosynthesis</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>In Situ Hybridization</subject><subject>Lymphokines - biosynthesis</subject><subject>Matrix Metalloproteinase 1 - biosynthesis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Prognosis</subject><subject>Proto-Oncogene Protein c-ets-1</subject><subject>Proto-Oncogene Proteins - biosynthesis</subject><subject>Proto-Oncogene Proteins c-ets</subject><subject>RNA, Messenger - metabolism</subject><subject>Time Factors</subject><subject>Transcription Factors - biosynthesis</subject><subject>Tumors</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Vascular Endothelial Growth Factors</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpN0FtLwzAUB_AiipvTryABwbdC0tyaxzGmDnYRb68hTdM12jYzWat-ewNO8ekcDj_O4fyPkjGilKc4Y_Q49pDnKSQ4GyVnIbxCiAiC5DQZIZQJnhE-Tl7m-5AisDIhmG5rPHhYT8H8c-fjwLoOLAJQYO0G04CV8m8RuArcO-fBY-8HO6gG2A5sBuWt6sBMeW0716rz5KRSTTAXhzpJnm_mT7O7dLm5Xcymy7TOGNunRUkMQ5yaqhAVFILxnBBawpKrQimoSy4EFhSavITaZAyRnJJSIM2qomKU4Uly_bN35917b8JetjZo0zSqM64PknOIBcJ5hJcH2BetKeXO21b5L_mbRARXB6CCVk3lVadt-HMCkyz_d6-22_rDeiN1dMbHuEz8vZZcYkkpwt-ZSXPE</recordid><startdate>20010301</startdate><enddate>20010301</enddate><creator>DAVIDSON, Ben</creator><creator>REICH, Reuven</creator><creator>GOLDBERG, Iris</creator><creator>GOTLIEB, Walter H</creator><creator>KOPOLOVIC, Juri</creator><creator>BERNER, Aasmund</creator><creator>BEN-BARUCH, Gilad</creator><creator>BRYNE, Magne</creator><creator>NESLAND, Jahn M</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20010301</creationdate><title>Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma</title><author>DAVIDSON, Ben ; REICH, Reuven ; GOLDBERG, Iris ; GOTLIEB, Walter H ; KOPOLOVIC, Juri ; BERNER, Aasmund ; BEN-BARUCH, Gilad ; BRYNE, Magne ; NESLAND, Jahn M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h266t-bd4e6175efb9f099678445d0d7abaa0cd7993950e8d0ce2614854d91c6fbf6563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Endothelial Growth Factors - biosynthesis</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Fibroblast Growth Factor 2 - biosynthesis</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>In Situ Hybridization</topic><topic>Lymphokines - biosynthesis</topic><topic>Matrix Metalloproteinase 1 - biosynthesis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Prognosis</topic><topic>Proto-Oncogene Protein c-ets-1</topic><topic>Proto-Oncogene Proteins - biosynthesis</topic><topic>Proto-Oncogene Proteins c-ets</topic><topic>RNA, Messenger - metabolism</topic><topic>Time Factors</topic><topic>Transcription Factors - biosynthesis</topic><topic>Tumors</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Vascular Endothelial Growth Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DAVIDSON, Ben</creatorcontrib><creatorcontrib>REICH, Reuven</creatorcontrib><creatorcontrib>GOLDBERG, Iris</creatorcontrib><creatorcontrib>GOTLIEB, Walter H</creatorcontrib><creatorcontrib>KOPOLOVIC, Juri</creatorcontrib><creatorcontrib>BERNER, Aasmund</creatorcontrib><creatorcontrib>BEN-BARUCH, Gilad</creatorcontrib><creatorcontrib>BRYNE, Magne</creatorcontrib><creatorcontrib>NESLAND, Jahn M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DAVIDSON, Ben</au><au>REICH, Reuven</au><au>GOLDBERG, Iris</au><au>GOTLIEB, Walter H</au><au>KOPOLOVIC, Juri</au><au>BERNER, Aasmund</au><au>BEN-BARUCH, Gilad</au><au>BRYNE, Magne</au><au>NESLAND, Jahn M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2001-03-01</date><risdate>2001</risdate><volume>7</volume><issue>3</issue><spage>551</spage><epage>557</epage><pages>551-557</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Ets-1 proto-oncogene is a transcription factor involved in several cellular functions, including the activation of several
proteases participating in tumor invasion and metastasis. The objective of this study was to analyze the possible correlation
between Ets-1 mRNA expression and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely
different disease outcome. Sections from 66 primary ovarian carcinomas and metastatic lesions from 41 patients diagnosed with
advanced-stage ovarian carcinoma (International Federation of Gynecologists and Obstetricians stages III and IV) were evaluated
for expression of Ets-1 using mRNA in situ hybridization. Patients were divided into long-term ( n = 17) and short-term ( n = 24) survivors. The mean values for disease-free survival and overall survival were 116 and 133 months for long-term survivors,
as compared to 3 and 21 months for short-term survivors, respectively. Expression of Ets-1 mRNA was detected in carcinoma
cells and stromal cells in 28 of 66 (42%) and 22 of 66 (33%) lesions, respectively. Ets-1 expression showed an association
with mRNA expression of vascular endothelial growth factor ( P = 0.001 for carcinoma cells; P = 0.004 for stromal cells), basic fibroblast growth factor ( P = 0.049 for carcinoma cells), and membrane type-1 matrix metalloproteinase ( P = 0.045), which were previously studied in this patient cohort. Ets-1 mRNA was detected more often in both carcinoma and
stromal cells in tumors of short-term survivors ( P = 0.038 for carcinoma cells). In univariate survival analysis for all cases, Ets-1 expression in both tumor ( P = 0.018) and stroma ( P = 0.026) correlated with poor survival. These findings were reproduced in an analysis of primary tumors alone ( P = 0.039 for tumor cells; P < 0.001 for stromal cells). Ets-1 mRNA expression in stromal cells retained its predictive power in a multivariate survival
analysis in which all molecules studied previously in this patient cohort were included ( P = 0.007). To our knowledge, this is the first evidence associating Ets-1 mRNA expression and poor survival in human epithelial
malignancy. Ets-1 is thus a novel prognostic marker in advanced-stage ovarian carcinoma. The association between Ets-1 mRNA
expression and the expression of membrane type-1 matrix metalloproteinase and angiogenic genes, first documented here in a
study of patient material, points to the central role of this transcription factor in tumor progression in ovarian carcinoma.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>11297247</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2001-03, Vol.7 (3), p.551-557 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77039138 |
| source | MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Disease Progression Disease-Free Survival Endothelial Growth Factors - biosynthesis Female Female genital diseases Fibroblast Growth Factor 2 - biosynthesis Gynecology. Andrology. Obstetrics Humans In Situ Hybridization Lymphokines - biosynthesis Matrix Metalloproteinase 1 - biosynthesis Medical sciences Middle Aged Multivariate Analysis Ovarian Neoplasms - metabolism Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Prognosis Proto-Oncogene Protein c-ets-1 Proto-Oncogene Proteins - biosynthesis Proto-Oncogene Proteins c-ets RNA, Messenger - metabolism Time Factors Transcription Factors - biosynthesis Tumors Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors |
| title | Ets-1 Messenger RNA Expression Is a Novel Marker of Poor Survival in Ovarian Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A37%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ets-1%20Messenger%20RNA%20Expression%20Is%20a%20Novel%20Marker%20of%20Poor%20Survival%20in%20Ovarian%20Carcinoma&rft.jtitle=Clinical%20cancer%20research&rft.au=DAVIDSON,%20Ben&rft.date=2001-03-01&rft.volume=7&rft.issue=3&rft.spage=551&rft.epage=557&rft.pages=551-557&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E77039138%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77039138&rft_id=info:pmid/11297247&rfr_iscdi=true |